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Summary
Purpose: To identify prognostic factors in patients with chemo-
sensitive relapsed Hodgkin's disease treated by high-dose che-
motherapy with autologous progenitor cell transplantation
(HDQ and to compare the duration of treatment-free remis-
sion prior to HDC with the progression-free survival after
HDC in individual patients.
Patients and methods: Forty-five consecutive patients were
analyzed retrospectively. We devised an index of pretreatment
intensity (IPTI) based number of different chemo- and radio-
therapy regimens given between diagnosis and HDC and on
the duration of disease.
Results: With a median follow-up of 47 months the post-
transplant event-free survival (EFS) was 44% and the overall
survival. (OAS) was 62% at four years. The IPTI allowed to
discriminate between a low and a high-risk group with a four-
year post-transplant EFS of 66% and 11% and a OAS of 87%
and 28%, respectively (P = 0.0001). Of the 39 patients with
sufficient follow-up after HDC, post-transplant EFS lasted on
average ^ 18.5 months longer than the pretransplant treat-
ment-free remission.
Conclusions: HDC with the CBV regimen confers significant
benefit to patients with chemosensitive relapsed Hodgkin's
disease. The IPTI may help to select patients with a good
response to HDC and to identify poor prognosis patients suit-
able for experimental protocols or palliative care only.
Key words: ABMT, high-dose therapy, Hodgkin's disease,
PBSCT, prognostic factor
Introduction
High-dose chemotherapy and autologous progenitor cell
transplantation (HDC) has gained wide acceptance for
patients with a relapse of Hodgkin's disease after ad-
equate systemic therapy [1-3]. The only randomized
trial [4] comparing conventional dose with HDC had to
be terminated early because of a significant advantage
for the high-dose arm and the unwillingness of patients
to accept conventional therapy. Because of the current
impossibility for further randomized studies, alternative
methods to determine a possible benefit of HDC need to
be developed. Yuen et al. [2] demonstrated a superior
event free survival with HDC compared to conventional
salvage therapy using a matched case control study.
An alternative way would be to compare the evolution
of the disease prior to and after HDC for each individ-
ual patient. Progression-free survival tends to become
shorter after each successfully treated relapse. Progres-
sion-free survival after HDC lasting longer than the last
treatment-free remission prior to salvage therapy would
therefore indicate a benefit of HDC.
Beside looking for a potential benefit of HDC it
would also be important to identify patients for whom
HDC is ineffective and thus could be treated with new
experimental approaches or palliative therapy only.
So far, no widely accepted parameters to identify risk
groups exist. Conventional risk factors as determined at
initial presentation or at relapse do not seem to signifi-
cantly influence the post-transplant course of disease [5-
7]. Many such factors have yielded prognostic power
only in a minority of the studies. Horning et al. [3] and
Reece et al. [8] described different risk scores using the
presence or absence of several factors to identify a good
prognosis group. However, the patients of the poor
prognosis group still had a progression-free survival of
41% at four years in one study [3]. The ability to ever
achieve a complete remission [5] is a notoriously soft
endpoint, since it is influenced by the stringency of
response evaluation. The number of pre-transplant
chemotherapy regimens [9, 10] and duration of the last
treatment-free pre-transplant remission [2, 11, 12] have
not been found relevant in all studies. After failing
to identify disease related prognostic factors in our pa-
tients with often multiple chemosensitive relapses of
Hodgkin's disease treated with HDC, we hypothesized
that survival after HDC might depend on the aggres-
siveness of the disease, which might be best reflected by
an index of pretreatment intensity (IPTI) based on the
number of chemotherapy or radiotherapy regimens be-
fore HDC and the time elapsed from the first therapy to
HDC.
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Patients and methods
Patient selection
From May 1987 to August 1996, all patients aged 16-60 years with
histologically or cytologicaUy proven relapsed Hodgkin's disease were
evaluated for inclusion into our study of HDC with autologous pro-
genitor cell support, on the condition they had relapsed after at least
one anthracycline-contairung chemotherapy regimen, i.e., either after
ABVD, alternating MOPP/ABVD, hybrid MOPP-ABV, or a similar
regimen given for an appropriate number of cycles. To reduce the
tumor volume, all patients underwent conventional salvage regimens
prior to HDC. At the time of HDC patients were required to have non-
bulky disease (< 5 cm in CT-scans) and no bone marrow involvement
exceeding 5% of the total marrow. Most patients were initially treated
at other institutions and referred to the participating hospitals either
before or during conventional salvage therapy. Patients with severe
cardiopulmonary, renal, endocrine, neuropsychiatric or infectious dis-
ease or lack of informed consent were excluded from HDC. Six patients
treated during the study period were not included into the present
analysis because they could not receive high-dose chemotherapy: two
patients refused HDC. One of them remains in complete remission, the
other relapsed with refractory progressive disease. One patient had
complications from further conventional salvage therapy precluding
HDC, and three patients showed refractory, progressive high-volume
disease before HDC could be initiated.
Salvage chemotherapy and harvest of autologous progenitor cells
All patients with relapsed Hodgkin's disease received conventional
salvage chemotherapy depending upon pretreatment and consisting
either of MOPP, hybrid MOPP-ABV, ABVD, EPOCH or an anthra-
cycline-free regimen containing streptozotocin, mechlorethamine, and
DTIC developed at our institution. As soon as at least a minor
response to the conventional salvage therapy could be documented
progenitor cell harvest was performed, mostly by bone marrow harvest
three to four weeks after prior chemotherapy. Peripheral blood pro-
genitor cell (PBPC) were mobilized by chemotherapy and filgrastim in
patients with previous pelvic irradiation, bone marrow infiltration,
insufficient bone marrow harvest, and as a general policy since 1995.
No purging procedures were done prior to progenitor cell retransfu-
sion. CFU-GM counts of >2.0 x 104/kg or CD34+ cells of > 1.0 x
106/kg were required.
High-dose chemotherapy, progenitor cell support, and supportive
measures
The CBV regimen was used for HDC in all patients and consisted of
cyclophosphamide 1500 mg/m2 at days 1-4, etoposide 300 mg/m2 at
days 1-3 and BCNU 300 mg/m2 at day 1. Hyperdiuresis and mesna
750 mg/m2 at days 1-5 were used for uroprotection. Autologous
progenitor cells were injected at day 8. Patients presenting with bulky
disease at relapse or persistence of a residual mass of unknown dignity,
received pre- or post-transplant involved field irradiation, if not pre-
cluded by previous radiotherapy. With the exception of the first two
patients prophylactic cotrimoxazole was given three times weekly for
three months after HDC. Fever > 38 °C was treated with antibiotics,
amphothericine-B and aciclovir according to institutional guide lines.
All blood products were irradiated with 1500 cGy. Leukocyte-depleted
erythrocytes were given and single donor platelet concentrates were
used restrictively according to published hospital guidelines [13]. The
first 12 patients were treated without colony stimulating factors There-
after, filgrastim was started the day after progenitor cell retransfusion
and given until recovery of absolute neutrophil counts to > 1.0 x io'/l
for three consecutive days [14].
Risk factors, definitions of intervals and response, and statistics
Patient's charts were reviewed (by JLM or WL) and risk factors
present at diagnosis and at the last pre-transplant relapse recorded.
Disease duration was calculated as the time from diagnosis to retrans-
fusion of the autologous progenitor cells. The duration of the last pre-
transplant remission (PTR) was calculated from the last day of prior
therapy to the day of confirmed pre-transplant relapse. Post-transplant
event-free survival (EFS) was calculated from the day of progenitor cell
retransfusion to either the day of confirmed relapse, death due to
causes other than tumor progression or the last control. The overall
survival after HDC (OAS) was calculated from the date of progenitor
cell retransfusion to the date of death due to any cause or the date of
the last control. Probabilities of EFS and OAS were calculated using
the method of Kaplan-Meier [15]. Survival differences between sub-
groups were analyzed by the log-rank test. Pretransplant remission
duration was compared to the post-transplant EFS by the two-tailed
paired r-test.
Response evaluation prior and three months after HDC was done
by CT-scans. The notoriously difficult distinction between partial
remission (PR) and complete remission with residual disease of un-
known significance (CRu) was pragmatically solved as follows: Pa-
tients without clinical and laboratory signs of active Hodgkin's disease
and with residual masses of < 5 cm were retrospectively considered to
be in complete response (CR) at the time of examination, if the
residual mass remained unchanged or had decreased without further
therapy at the following examinations. Any notion of tumor progres-
sion after any degree of response was used to define a relapse. Patients
were evaluated clinically and with appropriate radiographic exams at
regular intervals not distinct from those used after first-line therapy
(approximately every three months for the first year, at least every six
months for the second and third year and at least once during the
following years).
Index of pretreatment intensity
To quantify the aggressiveness of disease we chose an index of pretreat-
ment intensity (IPTI) which is based on the number of chemotherapy
or radiotherapy regimens before HDC and the time elapsed from the
first therapy to HDC. The number of regimens was defined as follows:
Number of different chemotherapy regimens (No. RCT*) and of tempo-
rally separated radiation therapies (No. RRTI) given since diagnosis.
The IPTI was calculated by dividing the number of regimens by the
time elapsed from the first therapy to HDC measured in years:
IPTI = (No. RCTX + No. RRTx)/Time (measured in fractions of
years) from the date of diagnosis to the date of HDC
The cut-off values for the IPTI were modeled to best discriminate
between either two or three patient groups of similar size.
As an example, a first-line regimen with MOPP-ABV hybrid
(counted as one regimen) followed by a salvage regimen for relapse
before HDC two years after diagnosis gives an IPTI of 1.0 (Ren = 2).
The IPTI would rise to 1.5, if a consolidating radiotherapy to the
mediastinum had been added (Ren = 2, RRTX = 1) within the same
time, but would drop to 0.33, had the time elapsed from the first
therapy to HDC been six years with a number of two regimens.
MOPP-ABV hybrid, planned sequential or alternating MOPP/ABVD
or similar multidrug regimen were counted as only one regimen.
However, if a patient received an adequate number of MOPP cycles
and had to be treated after a treatment-free interval for relapse with the
same or a different single regimen, the number of treatments was
defined as 2. Irradiation with a mantle field or a mantle field with
extension to involved areas including cervical or splenic lymph nodes
was counted as one therapy. None of our patients received subtotal
nodal irradiation, but we suggest to count such an extensive treatment
as two regimens.
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Table 1 Patients characteristics. A ) OAS s 624a EFS = 441. a! 4 years
No. of patients
Age
Median
Range
Sex
—Female
Male
Number of relapses prior to
HDC
No. of chemotherapy regimen
prior to HDC
Radiotherapy regimen during
pretreatment
Radiotherapy after HDC
Total therapies (CTx+RTx)
prior to HDC
Mean
Range
45
34 years
18-60 years
45-patients
30 patients
1 in 25 patients, 2 in 13 patients, 3-
in 7 patients
2 in 27 patients, 3-6 in 18 patients
None in 12 patients, 1 in 20 patienl
2 in 9 patients, 3-4 in 4 patients
6 patients (2 patients with pre-tran
plant radiotherapy)
3.8
2-9
B) £PSb»«0'CT. logrank p = 0 25C5 D) EFS by disease dmat.on Logrank s = 0 0692
Results
Patient characteristics
All 45 consecutive patients with relapsed Hodgkin's dis-
ease treated with HDC at our institution were analyzed.
Patient demographics and therapy prior to HDC are
summarized in Table 1. Including conventionally dosed
salvage therapy, an average of 2.7 chemotherapy regimens
(range 2-6) was given. Radiotherapy prior to HDC was
given to 33 of the 45 patients. Radiotherapy was applied
twice in nine patients and three or four times in four
patients. Altogether the average number of regimens
prior to HDC was 3.8 (range 2-9). Twenty-five patients
had one relapse, 13 patients had two relapses, three
patients had three relapses, and two patients each had
four or five relapses prior to salvage therapy. The median
duration of the last treatment-free pre-transplant remis-
sion (PTR) was 6.3 months (range 0-52 months). The
median interval from diagnosis to HDC was 39 months
(range 9-198 months). The median calculated index of
pretreatment intensity (IPTI) was 1.12 (range 0.24-6.73).
At the time of HDC 14 patients had achieved a PR and
25 patients a CR with (5) or without (20) residual mass
of unknown significance of maximally 2-5 cm in diam-
eter. Five patients had discernible signs of tumor re-
growth after achieving a PR early during conventionally
dosed salvage and were transplanted because they still
had low volume disease as defined by our entry criteria
and barely fulfilled the progressive disease criteria of
25% increase in diameter from the time of best response.
These patients were termed to be refractory. The median
time of follow-up from the date of progenitor cell re-
transfusion to the last control (cut-off date: October 15,
1996) was 47 months (range 2-104 months).
Months after CBV with APCT Months atMf CBV with APCT
Figure 1. In Graph A the Kaplan-Meier estimates of post-transplant
overall survival (OAS, solid line) and event-free survival (EFS, dotted
line) are shown for all 45 patients with relapsed Hodgkin's disease. The
median post-transplant OAS is 62.3 months, the median EFS 32.0
months. OAS at 36 and 48 months is 66.0% and 61.6% respectively.
The corresponding post-transplant EFS values are 48.1% and 43.7%.
Graph B depicts the EFS for 27 patients with two chemotherapy
regimens prior to HDC (solid line) and for 18 patients with three or
more regimens (dotted line, P = n s.).
Graph C shows the EFS for patients with long pre-transplant remis-
sion duration (PTR > 12 months, solid line, n = 16) or short PTR
(< 12 months, dotted line, n = 29,P = 0.073).
Graph D shows the EFS for 26 patients with an interval from
diagnosis to HDC of >30 months (solid line) and for those 19 with
< 30 months (dotted line, P = 0.069).
Response to high-dose chemotherapy and early toxicity
Response to high-dose chemotherapy was assessed at
three months: Twenty-five patients remained at CRu or
CR, 13 patients in PR converted to CRu or CR, one
patient had no change and five patients had tumor pro-
gression. One patient who did not receive prophylactic
cotrimoxazole died in CR of Pneumocystis carinii pneu-
monia before hematologic recovery. All other patients
had complete and timely hematologic recovery.
Survival after high-dose chemotherapy and late toxicity
The post-transplant event-free survival (EFS) at four
years was 44 ± 9% and the overall survival (OAS) 62 ±
9% (Figure 1A). Seventeen patients have relapsed with
and 12 patients have died of Hodgkin's disease. Three
patients died of possible late toxicity, including respira-
tory syncytial viral pneumonia, chronic aggressive hep-
atitis B, and sudden death with a history of ventricular
arrhythmias.
To quantify the possible merits of high-dose chemo-
therapy, we compared the post-transplant EFS to the
last pre-transplant remission duration for each individ-
ual patient as shown in Figure 2. Six patients with no
evidence of disease were not evaluable for this compar-
ison, because their time of follow-up had not yet ex-
ceeded the duration of pre-transplant remission. In the
remaining 39 patients, the median post-transplant EFS
Pre- & post-transplant remission Table 2. Kaplan-Meier survival estimates and prognostic factors
(univariate analysis).
100
80
60
40
60
Post-transplant event-free survival
• Continuous remission (N=24)
• Retapse(N=17)
^ Death with NED (N=4)
Last pre-transplant remission
Figure 2. In this graph post-transplant event-free survival (EFS) is
compared with the duration of the last treatment-free pre-transplant
remission (PTR) of each patient. NED = no evidence of disease. '•*•'
denotes the six patients in continuos CR with an insufficient follow-up,
i.e., an EFS still shorter than their PTR, ' • ' marks the two relapsed
patients and the three patients deceased with NED and an EFS shorter
than their PTR, '• ' highlights the poor prognosis patients with an IPTI
> 1.2, and '*' indicates the five patients with tumor regrowth prior to
HDC. Median EFS for the 39 patients with a post-transplant follow-up
longer than the PTR is 18.2 months, whereas their median PTR was
6.0 months (paired r-test: P = 0.0005).
was ^ 18.2 months comparing favorably with the me-
dian duration of the pre-transplant remission of 6.0
months (P - 0.00005, average: ^28.9 vs. 10.4 months).
Thirty four patients (87%) had a post-transplant EFS
that was longer than their last pre-transplant remission.
The average value after subtraction of each patient's
duration of the pretransplant remission from the post-
transplant EFS was > 18.5 months (median: $sll.8
months). The average of the ratios of post-transplant
EFS over PTR of the individual patients was ^ 5.4 with
a median ratio of ^ 2.3.
Factors predicting post-transplant outcome
Tentative analysis of disease-related prognostic param-
eters like age, sex, histology, tumor bulk, extranodal in-
volvement, stage, and B-symptoms at diagnosis or re-
lapse showed no significant discriminating power in our
small series of patients (data not shown). Most conven-
Potential risk factors
No. of chemo- and radiation
therapies >4
Yes
No
No. of chemotherapy regimen > 2
Yes
No
Last pre-transplant remission
< 12 months
Yes
No
Time from diagnosis to HDC
< 30 months
Yes
No
Refractory to salvage therapy
Yes
No
Index of pretreatment intensity
(IPTI) >1.2
Yes
No
Index of pretreatment intensity
(IPTI) > 1.2 (with the five refrac-
tory patients excluded)
Yes
No
Post-transplant event-free survival
for all patients
Kaplan-Meier estimates of median
survival for all 45 patients
Follow-up since high-dose chemo-
therapy
No. of
patients
22
23
18
27
29
16
19
21
5
40
21
24
19
21
45
EFS at
4 years
44%
44%
29%
55%
39%
50%
34%
51%
20%
48%
11%
66%
12%
72%
48%
Event-free survival
Overall
Median
range =
Log-rank
test
P = 0.6665
/> = 0.2605
P = 0.0726
P = 0.0692
P = 0.0004
P = 0.0003
P = 0.0001
= 32 months
survival = 62 months
= 47,
2-104 months
tional treatment-related factors were not discriminating
good and poor prognosis patients as shown in Table 2.
Only patients refractory to salvage therapy did signifi-
cantly worse (P - 0.0004). The number of pre-transplant
chemotherapies failed to significantly influence post-
transplant EFS (Figure IB). Patients with a duration of
the last treatment-free pre-transplant remission of > 12
months showed a trend for better post-transplant EFS
(P = 0.073, Figure 1Q. A disease duration from diagno-
sis to HDC of ^ 30 months was associated with a trend
for better EFS (P = 0.069, Figure ID).
The only powerful predictor of post-transplant sur-
vival was the index of pretreatment intensity (IPTI).
Using a two-tier division (IPTI < 1.2 or ^ 1.2) the EFS
at four years after HDC was 66% for the good risk
group and 11% for the poor risk group {P - 0.0001)
(Figure 3). Post-transplant overall survival showed a
plateau at 87% for the good risk group and was 28% at
four years for the poor risk group with no patient surviv-
ing more than 62 months (P < 0.0001). The results were
practically identical, when the five patients with ques-
tionable chemosensitivity were excluded (EFS: 72% vs.
12%, OAS: 90% vs. 27%, P sj 0.0001).
789
A) EFS by IPTI; Logrank p = 0 0003
100 +
B) OAS by IPTI Logrank: p < 0.0001
Months after CBV wtrh APCT Months attfw CBV with
Figure 3. The Kaplan-Meier estimates of post-transplant event-free
(graph A) and overall (graph B) survival are depicted as a function of
the index of pretreatment intensity (IPTI). The good risk group (IPTI
< 1.2, solid lines, n = 24) shows a significantly better survival (log-rank
test P = 0.0003 (for EFS) and P < 0.0001 for OAS) than the high-risk
group (IPTI 3= 1.2, dotted lines, n = 21). Similar results were obtained
after exclusion of the five patients with discernible signs of tumor
regrowth prior to HDC (P = 0.0001 for EFS and P < 0.0001 for OAS,
graphs not shown, see Table 2).
Discussion
At least since the only randomized study of high-dose
chemotherapy with autologous progenitor cell support
(HDC) of Linch et al. [4] the strategy of HDC has
become accepted routine therapy at many centers [1-3].
Our survival data support the use of high-dose chemo-
therapy with CBV and progenitor cell transplantation as
salvage therapy for patients with relapsed Hodgkin's
disease. The OAS of 62% and the EFS of 44% at four
years are similar to the findings of many other studies
studies [2-5, 10, 12, 16-19]. The mortality rate of 2.2%
and no death since routine use of prophylactic cotri-
moxazole compares favorably with published studies.
This might be attributed to the moderate dose (300 mg/
sqm) of BCNU used or possibly to the faster hemato-
logic recovery with hematopoietic growth factors and or
peripheral progenitor cell support [14, 20, 21] used in
73% of the patients.
Although HDC is generally accepted for the treat-
ment of relapsed Hodgkin's disease, its benefits need to
be better defined. We attempted to do this comparing the
evolution of the disease prior to and after HDC for each
individual patient. Event-free survival after HDC lasting
longer than the last treatment-free remission prior to
salvage therapy might substantiate the benefit of HDC
in this disease. In 34 of 39 patients with sufficient follow-
up, the event-free survival after HDC surpasses the
duration of the pretransplant remission. The ^ 18.5
months longer duration of the post-transplant remission
than the pretransplant remission duration represents a
finding in support of a benefit of HDC in relapsed
Hodgkin's disease.
For whom does HDC work and for whom it doesn't?
It is well known that patients with progressive disease
prior to HDC despite extensive conventional pretreat-
ment do very poorly [2, 10, 12, 17, 22], a fact that can be
confirmed in our series as well, since only one of the five
patients termed refractory achieved a CR with a post-
transplant EFS of over 12 months duration. Besides
that, data concerning prognostic factors for post-trans-
plant survival by different authors are conflicting. Fac-
tors established at the time of initial presentation rarely
showed prognostic power in this setting. Our series may
be too small to identify prognostic factors. On the other
hand, if a factor can be found only after analysis of
hundreds of patients, they may not be clinically useful
because of only ~modest differences in survival. The
duration of the first or last treatment-free pre-transplant
remission (PTR) has been proposed as good prognostic
factor [2, 11, 12, 22], but discriminates long-term post-
transplant event-free survival (EFS) rather poorly in our
series of heavily pretreated patients and would certainly
not have been good enough to deny a patient undergoing
HDC. An explanation can be easily found in the fact
that the duration of PTR as prognostic parameter does
not consider the amount of treatment required to
achieve this remission. Turning to the number of differ-
ent therapeutic regimes [9, 10] does not solve the prob-
lem either, because the numbers can be equally high in
patients with a long history of ever relapsing and ever
responding Hodgkin's disease and those with minimally
responsive, rapidly progressing disease requiring fre-
quent changes of the treatment regimen. This would be
in line with the observation, that patients with a higher
number of relapses did better than those with HDC after
the first relapse in one study [10]. We therefore developed
an index of pretreatment intensity (IPTI) taking into
consideration both the number of the therapies given
and disease duration. The proposed index can be easily
calculated with the knowledge of a summary of the
patient's history and quantifies the aggressiveness of the
disease by our therapeutic activity to cope with it.
Using our index of pretreatment intensity one can
clearly state that the CBV-regimen as used in our series
of heavily pretreated patients is insufficient to really help
those roughly 35% with the most aggressive disease. The
EFS of our poor prognostic group is 11% at four years
even for patients responsive to conventional salvage
therapy. On the other hand, EFS remains at 66% after 4
years for the good prognostic group. In our hands, i.e.,
with our referral pattern and our mode of patient selec-
tion for HDC, the proposed index is much more power-
ful than any other proposed risk factor such as bulk at
presentation or residual mass at HDC [3, 12], female sex
[10], partial versus complete remission prior to HDC
[22, 23], performance status [9, 11, 24] or B-symptoms
[8], different locations of extranodal disease disease [3, 8,
24-26] and even age [27].
If the index of pretreatment intensity (IPTI) as pro-
posed in our study is confirmed in larger series or among
registry data, we would have an easily applicable and
effective tool to identify those patients with relapsed
Hodgkin's disease who benefit most from HDC and
autologous progenitor cell support. Patients not likely
to significantly benefit from conventional HDC could be
offered new experimental programs or palliative care
only.
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